WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

In Ireland, WuXi Biologics has sold a new vaccine plant to Merck & Co. for €500 million ($521 million). The New Jersey company was a natural buyer of the facility as it was the lone client WuXi ...

CMB International Securities analyst Jill Wu has maintained their bullish stance on WXIBF stock, giving a Buy rating on January 13.Stay Ahead ...

SHANGHAI, Jan. 2, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has ...

SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced an ...

WuXi Biologics' CEO Chris Chen has denied that the company’s sale of its less than four-year-old Ireland site is due to the threat of the US Biosecure Act, and said that the number of new ...

The facility, with a net book value of about $487 million, is a 15,520-square-meter, three-story vaccine manufacturing plant with 200 employees. The deal is expected to be completed in the first ...

WuXi Biologics (OTCPK:WXIBF) is reportedly selling its vaccine facility in Ireland to Merck (NYSE:MRK) as part of a previously announced plan to divest some of its assets. The China-based contract ...

Wuxi invested €200 million in 2019 to build the plant, which currently employs 200 people, alongside a biologics facilities it continues to operate. MSD says it will add 150 jobs to the Dundalk ...